laser eradication

Home>Tag:laser eradication
May 31 2023

Halberd CEO Mid-Quarter Update

By |2023-05-31T05:53:16-04:00May 31st, 2023|Investor News, News, Press Releases, Uncategorized, Update Letter|0 Comments

Jackson Center, PA May 31, 2023 – Halberd Corporation (OTC-PINK: "HALB”) has been progressing rapidly on several projects in so many areas that this mid-quarter update is intended to bring the public up to date on a few of the most significant efforts. Mississippi State University (MSU) has completed the impacts and sample collection for ...

Apr 20 2023

$HALB CEO, CTO and #YSU’s Dr. Sturrus Discuss CDC, Research Discoveries etc., on “The Street Reports Podcasts” Listen Now!

By |2023-04-19T17:57:22-04:00April 20th, 2023|Featured, Investor News, News, Uncategorized|0 Comments

Jackson Center, PA, April 20, 2023 – Halberd Corporation’s (OTC-PINK: "HALB") President & CEO, William A. Hartman, its Chief Technical Officer, Dr. Mitchell S. Felder, and Youngstown State University (YSU) Professor/lead researcher, Dr. Wm. Gregg Sturrus were interviewed on “The Street Reports” to discuss the company’s latest research discoveries and progress on eradicating CDC (Centers for ...

Apr 3 2023

Halberd’s Successful Meeting with CDC Leads to Expanded Testing of Antibiotic Resistant Pathogens

By |2023-04-03T05:07:20-04:00April 3rd, 2023|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, April 3, 2023 – Halberd Corporation (OTC PINK:HALB) on March 29th met with five representatives from the Centers for Disease Control and Prevention (CDC). The CDC discussed Halberd’s incredible success eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and deadly Candida auris samples previously provided by the CDC. Halberd participants ...

Mar 21 2023

Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University

By |2023-03-21T18:30:21-04:00March 21st, 2023|Investor News, Medical, News, Press Releases, Uncategorized|0 Comments

Jackson Center, PA, March 21, 2023 – Halberd Corporation (OTC PINK:HALB), leading up to the scheduled meeting with the Centers for Disease Control (CDC) on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E. coli samples previously provided by the CDC.  Using Halberd’s patented extracorporeal ...

Mar 14 2023

Halberd & Centers for Disease Control to Meet Regarding Eradication of Antibiotic Resistant Pathogens

By |2023-03-14T05:42:44-04:00March 14th, 2023|Featured, Investor News, Medical, Press Releases|0 Comments

Halberd’s patented process demonstrates eradication of multiple strains of antibiotic resistant bacteria and fungi in under 10 minutes. Jackson Center, PA, March 14, 2023 – Halberd Corporation (OTC PINK:HALB) is scheduled to meet with Center of Disease Control (CDC) representatives to discuss Halberd’s incredible success in eradicating multiple strains of antibiotic resistant (AR) E. coli ...

Feb 21 2023

Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria

By |2023-02-21T05:34:56-05:00February 21st, 2023|Featured, Investor News, Medical, News, Press Releases|0 Comments

Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in-vitro Jackson Center, PA, February 21, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under ten minutes.  Halberd’s patented extracorporeal process and patent-pending ...

Feb 8 2023

Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria

By |2023-02-08T04:58:45-05:00February 8th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing Jackson Center, PA, February 8, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples.  Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria ...

Dec 6 2022

Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication

By |2022-12-05T19:18:54-05:00December 6th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Halberd’s method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains. Jackson Center, PA December 6, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB).  Halberd will utilize its laser eradication ...

Nov 17 2022

Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint By Eradicating Cancer Disease Antigen Linked to Breast Cancer

By |2022-11-17T05:15:05-05:00November 17th, 2022|Featured, Investor News, Medical, News|0 Comments

Halberd Successful In Laboratory Tests In Eradicating All Five of The Top Cancer Disease Antigens Attempted To Date Jackson Center, PA, November 17, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in ...

Jun 21 2022

Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

By |2022-06-21T05:23:46-04:00June 21st, 2022|Featured, Investor News, News|0 Comments

Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC-PINK: "HALB”) announced the creation of a subgroup of researchers to focus on cancer treatment.  Halberd’s technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments. The subgroup will be guided ...

Go to Top